Cryosurgery for prostate cancer: new technology and indications.
Patients diagnosed with prostate cancer who elect to pursue active treatment of their disease must choose among the many available treatment alternatives. Several treatment options now exist for similar-stage disease (clinical T1-3N0M0), including radical prostatectomy, external beam radiation, prostate brachytherapy (PB), and cryosurgical ablation of the prostate (CSAP). This article reviews the current role of CSAP in the treatment of clinically localized prostate cancer. CSAP has a role in the primary treatment of men with high-risk, clinically localized prostate cancer (defined as PSA >10, Gleason score >or=7, or clinical stage >or= cT2B). CSAP (occasionally followed by external beam radiotherapy) appears to offer improved rates of cancer control over other types of single or combination therapies for this high-risk prostate cancer, and it is associated with an acceptable side-effect profile. CSAP should also be the treatment of choice for men with recurrent local disease who have undergone external beam radiotherapy or PB.
Benoit
R M
RM
Department of Urology, Allegheny General Hospital, 1209 Allegheny Tower, 625 Stanwix Street, Pittsburgh, PA 15222, USA. Rbenoit@triangleurology.com
Cohen
J K
JK
Miller
R J
RJ
D003452:Cryosurgery / Q000009:adverse effects / Q000379:methods* / Q000523:psychology; D006801:Humans; D008297:Male; D018579:Patient Selection; D011471:Prostatic Neoplasms / Q000601:surgery*; D012307:Risk Factors